Sugi Predict

Sugi Predict / Compounds / SCHEMBL1614040

SCHEMBL1614040

SCHEMBL1614040

COc1cc2c(=O)n(COC(=O)C(C)(C)C)cnc2cc1OCC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 3/20 0.45
▸ NSD2 O96028 2/20 0.44
▸ TNF P01375 3/20 0.43
▸ EHMT2 Q96KQ7 2/20 0.42
▸ EPHA2 P29317 4/20 0.41
▸ EPHB4 P54760 2/20 0.40
▸ KDM1A O60341 1/20 0.40
▸ RCOR1 Q9UKL0 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ DNMT3A Q9Y6K1 1/20 0.40
▸ TLR9 Q9NR96 1/20 0.40
▸ TLR7 Q9NYK1 1/20 0.40
▸ USP19 O94966 1/20 0.40
▸ ERBB2 P04626 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.39
▸ PDE4A P27815 1/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ PDE4C Q08493 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ ENPP1 P22413 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4377668 0.93 HDAC6 (0.45) HDAC6NSD2TNFEHMT2EPHA2
SCHEMBL1613534 0.89 HDAC6 (0.49) HDAC6TNFKDR
SCHEMBL1613324 0.85 HDAC6 (0.48) HDAC6TNFKDRUSP19HDAC3
Hydrochloric Acid SCHEMBL4373074 0.85 HDAC6 (0.48) HDAC6TNFKDRUSP19HDAC3
SCHEMBL7580235 0.85 EHMT2 (0.49) HDAC6NSD2TNFEHMT2TLR9
SCHEMBL5216513 0.85 HDAC6 (0.45) HDAC6TNFKDRPDE4APDE4D
SCHEMBL4380593 0.83 HDAC6 (0.44) HDAC6TNFKDRUSP19ENPP1
SCHEMBL6410009 0.83 TNF (0.44) HDAC6NSD2TNFEHMT2KDR
SCHEMBL4371036 0.82 HDAC6 (0.49) HDAC6TNFKDRUSP19ENPP1
SCHEMBL4380760 0.81 HDAC6 (0.51) HDAC6TNFEPHA2EPHB4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210276972-A1 Quinazoline Derivatives as VEGF Inhibitors GENZYME CORPORATION (US) 2021-09-09 — — US disclosed
US-20200262811-A1 Quinazoline Derivatives as VEGF Inhibitors GENZYME CORPORATION (US) 2020-08-20 — — US disclosed
US-10457664-B2 Quinazoline derivatives as VEGF inhibitors GENZYME CORPORATION (US) 2019-10-29 — — US disclosed
US-20190002433-A1 Quinazoline Derivatives as VEGF Inhibitors GENZYME CORPORATION (US) 2019-01-03 — — US disclosed
US-20180099946-A1 Quinazoline Derivatives as VEGF Inhibitors GENZYME CORPORATION (US) 2018-04-12 — — US disclosed
US-20160130249-A1 Quinazoline Derivatives as VEGF Inhibitors ASTRAZENECA AB (SE) 2016-05-12 — — US disclosed
US-9040548-B2 Quinazoline derivatives as VEGF inhibitors ASTRAZENECA AB (SE) 2015-05-26 — — US disclosed
US-20140121228-A1 Quinazoline Derivatives as VEGF Inhibitors ASTRAZENECA AB (SE) 2014-05-01 — — US disclosed
US-8642608-B2 Quinazoline derivatives as VEGF inhibitors ASTRAZENECA AB (SE) 2014-02-04 — — US disclosed
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 — — US disclosed
WO-2004014383-A1 COMBINATION OF ZD6474, AN INHIBITOR OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, WITH RADIOTHERAPY IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2004-02-19 — — WO disclosed
WO-2003045364-A2 USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-06-05 — — WO disclosed
EP-1313727-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2003-05-28 — — EP disclosed
WO-2002092578-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2002-11-21 — — WO disclosed
WO-2002092577-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2002-11-21 — — WO disclosed
WO-2002016352-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2002-02-28 — — WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 — — EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099946-A1 Quinazoline Derivatives as VEGF Inhibitors FLT4, FLT1, KDR HDAC6 2844/4885NSD2 4453/4885TNF 193/4885
US-20210276972-A1 Quinazoline Derivatives as VEGF Inhibitors FLT1, FLT4, KDR HDAC6 3137/4885NSD2 4589/4885TNF 261/4885
US-10457664-B2 Quinazoline derivatives as VEGF inhibitors FLT1, FLT4, KDR HDAC6 2999/4885NSD2 4377/4885TNF 212/4885
US-20160130249-A1 Quinazoline Derivatives as VEGF Inhibitors FLT1, FLT4, KDR HDAC6 3041/4885NSD2 4319/4885TNF 182/4885
US-20140121228-A1 Quinazoline Derivatives as VEGF Inhibitors FLT4, FLT1, KDR HDAC6 2668/4885NSD2 3957/4885TNF 1259/4885
US-20200262811-A1 Quinazoline Derivatives as VEGF Inhibitors FLT1, FLT4, KDR HDAC6 3041/4885NSD2 4319/4885TNF 182/4885
US-20190002433-A1 Quinazoline Derivatives as VEGF Inhibitors FLT1, FLT4, KDR HDAC6 2999/4885NSD2 4377/4885TNF 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.